Lonza, a biological manufacturer, has announced the expansion of mammalian production capacity at its Slough (UK) facility
Lonza's facility in Slough
This expansion will significantly increase the existing single-use manufacturing capacity in Slough while allowing current operations to continue without interruption Lonza said.
The site provides cell line construction, process development and clinical manufacturing services for mammalian-derived biotherapeutics and is to have two 1000L single-use bioreactors installed.
The increase in bioreactor capacity continues the implementation of single-use technologies at the Slough site and complements existing single-use equipment for both seed train systems and downstream processing, including chromatography, filtration and ultrafiltration unit operations.
The new reactors are equipped with controllers that enable parallel reactor operations, expanded process capabilities with flexible operating scales and bioreactor types.
Lonza said use of these technologies supports its ability to accommodate a variety of customer projects and processes across scales and clinical phases.
Michael Brown, head of operations for clinical development, Lonza pharma and biotech, said: “The ease of installation, commissioning and validation of single-use bioreactors allows us to meet the increased market demand for clinical manufacturing.”